By Fineline Cube China’s National Healthcare Security Administration (NHSA) and Ministry of Finance jointly issued a comprehensive notice strengthening supervision of personal medical account usage under the basic medical insurance (BMI) scheme for employees at designated retail pharmacies. The directive mandates provincial authorities to implement a “white list” system by September 2026, explicitly excluding health supplements and daily necessities while requiring strict oversight of eligible medical products.
Regulatory Framework & Implementation Timeline
| Requirement | Deadline | Scope |
|---|---|---|
| White List Implementation | End of September 2026 | Provincial-level healthcare security authorities |
| Eligible Items | Immediate effect upon white list publication | Drugs, medical devices, medical consumables only |
| Excluded Items | Immediate prohibition | Health supplements, daily necessities |
| Compliance Monitoring | Ongoing | Enhanced fund oversight and pharmacy management |
White List Eligibility Criteria
Items qualifying for inclusion on provincial white lists must meet strict regulatory and clinical standards:
- Regulatory Approval: Must be formally approved or registered by drug regulatory authorities for retail pharmacy sale
- Medical Necessity: Must be closely related to treatment with strong medical attributes
- Pricing Standards: Must demonstrate reasonable pricing aligned with therapeutic value
- Product Categories: Limited to drugs, medical devices, and medical consumables only
Prohibited Practices & Enforcement Measures
The notice establishes zero-tolerance policies for retail pharmacy misconduct:
- Consumer Inducement: Strictly prohibited from inducing consumer spending through promotional tactics
- Price Inflation: Inflating prices to maximize personal account utilization is forbidden
- Agreement-Based Management: Enhanced contractual oversight of designated retail pharmacies
- Fund Protection: Intensified oversight of healthcare security funds to prevent misuse
Market Impact & Industry Implications
- Retail Pharmacy Revenue: Estimated 15-20% revenue impact for pharmacies heavily reliant on personal account purchases of excluded items
- Pharmaceutical Manufacturers: Shift toward medically necessary products with clear therapeutic indications
- Health Supplement Sector: Complete exclusion from insurance reimbursement eliminates significant sales channel
- Consumer Behavior: Patients must now pay out-of-pocket for non-medical items previously covered through personal accounts
Strategic Rationale & Policy Objectives
- Basic Protection Principle: Reinforces the “basic protection” function of employee medical insurance, preventing scope creep into lifestyle products
- Fund Sustainability: Protects healthcare security fund integrity amid rising medical costs and aging population pressures
- Rational Utilization: Promotes reasonable, prudent, flexible, and well-regulated approach to personal account management
- Healthcare Quality: Ensures insurance funds support evidence-based medical care rather than discretionary purchases
Implementation Challenges & Opportunities
- Provincial Coordination: Variations in white list composition across provinces may create market fragmentation
- Digital Infrastructure: Requires robust medical code management systems for real-time eligibility verification
- Compliance Costs: Pharmacies face increased administrative burden for product categorization and transaction monitoring
- Innovation Incentives: Encourages development of high-value medical products that meet stringent white list criteria
Broader Healthcare Reform Context
This directive aligns with China’s comprehensive healthcare reform agenda:
- Insurance System Integrity: Part of broader efforts to strengthen basic medical insurance sustainability
- Value-Based Care: Supports transition toward outcomes-focused healthcare delivery
- Regulatory Harmonization: Complements ongoing efforts to standardize medical product classification and pricing
- Anti-Corruption Measures: Addresses historical concerns about insurance fund misuse in retail pharmacy settings
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory implementation, market impacts, and policy outcomes. Actual results may differ due to risks including provincial implementation variations, industry adaptation challenges, and evolving regulatory interpretations.-Fineline Info & Tech